Candel Therapeutics, Inc.
Candel Therapeutics, Inc. (CADL) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cadl · stock forecast · 10 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$15.00
Consensus
$15.00
+76.0% upside
Low
$15.00
Median: $15 · Last Close: $8.53
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $8.81 | ↑ 3.34% |
1-day model range: $8.73–$8.89. Peak: $8.89 (+3.34%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $7 | -14.1% |
| 2028 | $7 | -20.8% |
| 2029 | $6 | -24.2% |
| 2030 | $6 | -26.0% |
| 2031 | — | -26.9% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CADL · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-18 | Citigroup | Maintains | Buy→Buy |
| 2026-03-13 | Citigroup | Maintains | Buy→Buy |
| 2026-03-13 | Canaccord Genuity | Maintains | Buy→Buy |
| 2025-12-08 | Stephens & Co. | Maintains | Overweight→Overweight |
| 2025-11-21 | Freedom Broker | Maintains | Buy→Buy |
| 2025-11-14 | Citigroup | Maintains | Buy→Buy |
| 2025-09-29 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-03 | B of A Securities | Downgrade ↓ | Buy→Neutral |
| 2025-04-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Candel Therapeutics, Inc. (CADL) stock. Of the recent 26 rating actions, 0 were upgrades and 1 were downgrades. 10 analysts currently cover CADL.
Analyst Recommendation Trends
CADL analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 3 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$93M
↓ 42.2% YoY
Revenue Next Year
$42M
↓ 54.6% YoY
EPS This Year
$-0.94
EPS Next Year
$-0.67
↓ 28.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast CADL EPS of $-0.94 for the current fiscal year, based on estimates from 4 analysts. The CADL revenue forecast is $93M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CADL stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CADL price target is $15.00 (+76.0% upside), with an analyst consensus of Buy.
The CADL short-term stock prediction for tomorrow is $8.81 (+3.34%). The CADL stock price prediction for 2027 estimates an average of $7. The CADL stock prediction for 2030 projects a range of $6–$7.
Candel Therapeutics, Inc. trades on NASDAQ under the ticker CADL. The CADL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 90% of covering analysts.
Frequently asked questions
CADL forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month CADL price target is $15.00, with a high forecast of $15.00 and a low of $15.00. The median price target is shown in the chart above when available. This implies +76.0% potential upside from the current price of $8.53.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.